Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Argipressin is a peptide hormone with vasoconstrictive and antidiuretic activities that binds to the vascular arginine vasopressin receptor, V1, with Kd values of 1.31 and 1.44 nM in A7r5 rat aortic smooth muscle cells and neonatal rat cardiomyocytes, respectively.1,2 It also stimulates the intracellular release of calcium in A7r5 cells (EC50 = 5 nM).3 In rat models, argipressin induces hypertension and tachycardia when injected into the lateral septal nuclei at a dose of 100-400 ng and increases heart rate and mean arterial pressure (MAP) when injected into the medial amygdaloid body at a dose of 150-600 ng.4,5
WARNING This product is not for human or veterinary use.
1. Multiple signaling pathways of V1-
2. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. 69(1), 239-245 (1991).
3. Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ. Res. 78(5), 813-820 (1996).
4. Cardiovascular effects of injection of argipressin into lateral septal nuclei in rats. Zhongguo Yao Li Xue Bao. 17(1), 49-52 (1996).
5. Effects of argipressin injected into medial amygdaloid body on blood pressure and heart rate in rats. Zhongguo Yao Li Xue Bao. 14(2), 118-120 (1993).